More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular ...

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

Humana has refiled its lawsuit against the federal government over its Medicare Advantage ratings, with billions of dollars ...

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

New AI chatbot called Ash is different, Slingshot founders say, because its training model is based on real therapeutic ...

A federal report found that an organ procurement organization ignored signs of life in patients when authorizing attempted ...

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Sarepta Therapeutics faces an "arduous path” to try to get its gene therapy for Duchenne muscular dystrophy back onto the market, a senior FDA official told STAT.